Skip to content

Walter Dunn

5 papers in the library · 17 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis.

Journal of Affective Disorders October 12, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Treatment-resistant depression (TRD) affects 30-60% of individuals with major depressive disorder and carries substantial morbidity and healthcare costs. Intravenous (IV) ketamine (KET) is a rapid-acting antidepressant, but benefits are often transient, prompting augmentation to sustain efficacy or improve tolerability. We conducted a systematic review and meta-analysis of randomized controlled...

Role of ketamine in the treatment of substance use disorders: A systematic review.

Journal of Substance Use and Addiction Treatment August 1, 2025 Reinhard Janssen-Aguilar, Shakila Meshkat, Ilya Demchenko et al. 12 citations

Substance Use Disorders (SUDs) involve diminished control, risky use, impaired social interactions, and physical dependence. Despite their global prevalence and burden, treatment options remain limited. Ketamine (KET), an NMDA receptor antagonist, may aid SUD treatment by modulating glutamatergic neurotransmission. This systematic review evaluates KET's role in SUD treatment. This review...

DOI: 10.1016/j.josat.2025.209705 (opens in new tab) Full text (opens in new tab) Sud Systematic review Addiction treatment Ketamine therapy +3

Psychedelics and Suicide-Related Outcomes: A Systematic Review

Journal of Clinical Medicine February 20, 2025 Shakila Meshkat, Taha Malik, Jennifer Swainson et al. 3 citations

Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscores the need for alternatives. Psychedelic therapies may rapidly reduce suicide risk. This systematic review evaluates impact of psychedelic therapies on suicide-related outcomes. Methods: A systematic search of MEDLINE, Embase, PsycINFO, and...

MDMA for treatment of PTSD and neurorehabilitation in military populations

Neurorehabilitation September 27, 2024 Walter Dunn, Anya K. Bershad, David E. Krantz et al. 2 citations

BACKGROUND: Neurorehabilitation in military populations is complicated by higher rates of PTSD and unique characteristics of military institutions. These factors can adversely impact the patient-therapist therapeutic alliance and engagement with the rehabilitation process leading to poorer outcomes. MDMA is a non-classical psychedelic with pro-social and fear regulating properties....

DOI: 10.3233/nre-230270 (opens in new tab) Full text (opens in new tab) MDMA Neurorehabilitation Alliance Psychotherapist +1